Therefore, the prevention of Aβ-induced BMAL1 and CBP degradation, or improved Aβ clearance by restoration of the sleep-wake cycle, could be novel therapeutic targets for AD pathogenesis, and warrant further investigation. Here, CREBBP is linked to Alzheimer disease.